Gao Chun-hua, Yang Yue-tao, Shi Feng, Wang Jun-yun, Steverding Dietmar, Wang Xia
National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Laboratory of Parasite and Vector, Ministry of Public Health, National Centre for International Research on Tropical Diseases, WHO Collaborating Center for Malaria, Schistosomiasis and Filariasis, Shanghai, China.
BioMedical Research Centre, Norwich Medical School, Norwich Research Park, University of East Anglia, Norwich, United Kingdom.
PLoS Negl Trop Dis. 2015 Jun 30;9(6):e0003902. doi: 10.1371/journal.pntd.0003902. eCollection 2015.
Visceral leishmaniasis (VL) is a life-threatening disease caused by protozoan parasites of the Leishmania donovani complex. Early case detection followed by adequate treatment is essential to the control of VL. However, the available diagnostic tests are either invasive and require considerable expertise (parasitological demonstration of the parasite in tissue smears) or unable to distinguish between past and active infection (serological methods). Therefore, we aimed to develop a lateral flow assay in the form of an immunochromatographic test (ICT) device based on the detection of a circulating Leishmania antigen using monoclonal antibodies (mAbs).
METHODOLOGY/PRINCIPAL FINDINGS: mAbs were produced by fusion of murine myeloma cells with splenocytes isolated from a mouse immunized with L. donovani soluble crude antigen. Out of 12 cloned hybridoma cell lines, two secreted mAbs recognizing the same leishmanial protein. These mAbs were used to produce an ICT as a sandwich assay for the detection of circulating antigen in serum and blood samples. The ICT was evaluated with 213 serum samples from VL patients living in VL endemic areas in China, and with 156 serum samples from patients with other diseases as well as 78 serum samples from healthy donors. Sensitivity, specificity and diagnostic efficiency of the new ICT was 95.8%, 98.7% and 97.3%, respectively. Compared with a commercially available antibody detecting ICT, our antigen-based ICT performed slightly better.
CONCLUSION/SIGNIFICANCE: The newly developed ICT is an easy to use and more accurate diagnostic tool which fulfils the performance and operational characteristics required for VL case detection under field and laboratory conditions. As our ICT detects a circulating antigen, it will also be useful in monitoring treatment success and diagnosing VL in immunocompromised patients.
内脏利什曼病(VL)是由杜氏利什曼原虫复合体的原生动物寄生虫引起的一种危及生命的疾病。早期病例检测并随后进行充分治疗对于控制VL至关重要。然而,现有的诊断测试要么具有侵入性且需要相当专业的知识(在组织涂片中进行寄生虫的寄生虫学证明),要么无法区分既往感染和活动性感染(血清学方法)。因此,我们旨在开发一种基于使用单克隆抗体(mAb)检测循环利什曼原虫抗原的免疫层析试验(ICT)形式的侧向流动分析方法。
方法/主要发现:通过将鼠骨髓瘤细胞与从用杜氏利什曼原虫可溶性粗抗原免疫的小鼠中分离的脾细胞融合来产生mAb。在12个克隆的杂交瘤细胞系中,有两个分泌识别相同利什曼原虫蛋白的mAb。这些mAb被用于生产一种ICT,作为一种夹心分析法来检测血清和血液样本中的循环抗原。该ICT用来自中国VL流行地区的213份VL患者血清样本、156份其他疾病患者血清样本以及78份健康供体血清样本进行了评估。新ICT的敏感性、特异性和诊断效率分别为95.8%、98.7%和97.3%。与市售的抗体检测ICT相比,我们基于抗原的ICT表现略好。
结论/意义:新开发的ICT是一种易于使用且更准确的诊断工具,满足了在现场和实验室条件下进行VL病例检测所需的性能和操作特征。由于我们的ICT检测循环抗原,它在监测治疗效果和诊断免疫功能低下患者的VL方面也将是有用的。